ADSTILADRIN

This brand name is authorized in United States

Active ingredients

The drug ADSTILADRIN contains one active pharmaceutical ingredient (API):

1 Nadofaragene firadenovec UNII 0OOS09O1FH - NADOFARAGENE FIRADENOVEC

Nadofaragene firadenovec is a non-replicating adenoviral vector-based gene therapy designed to deliver a copy of a gene encoding a human interferon-alfa 2b (IFNα2b) to the bladder urothelium. Intravesical instillation of nadofaragene firadenovec results in cell transduction and transient local expression of the IFNα2b protein that is anticipated to have anti-tumor effects. Read about Nadofaragene firadenovec

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ADSTILADRIN Suspension for intravesical instillation	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XL10		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XL Antineoplastic cell and gene therapy
Discover more medicines within L01XL10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 55566-1050